Intravascular Stem Cell Bioreactor for Prevention of Adverse Remodeling After Myocardial Infarction

BACKGROUND: Prevention of adverse remodeling after myocardial infarction (MI) is an important goal of stem cell therapy. Clinical trial results vary, however, and poor cell retention and survival after delivery likely limit the opportunity to exert beneficial effects. To overcome these limitations,...

Descripción completa

Detalles Bibliográficos
Autores principales: Johnston, Peter V., Hwang, Chao‐Wei, Bogdan, Virginia, Mills, Kevin J., Eggan, Elliott R., Leszczynska, Aleksandra, Wu, Katherine C., Herzka, Daniel A., Brinker, Jeffrey A., Schulman, Steven P., Banerjee, Monisha, Florea, Victoria, Natsumeda, Makoto, Tompkins, Bryon, Balkan, Wayne, Hare, Joshua M., Tomaselli, Gordon F., Weiss, Robert G., Gerstenblith, Gary
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2019
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6761667/
https://www.ncbi.nlm.nih.gov/pubmed/31340693
http://dx.doi.org/10.1161/JAHA.119.012351

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6761667/
https://www.ncbi.nlm.nih.gov/pubmed/31340693
http://dx.doi.org/10.1161/JAHA.119.012351

Ejemplares similares